Suboxone Film lawsuit update

Verified snapshot

The facts that anchor this dossier

Suboxone film is an important treatment for opioid use disorder, and FDA says its benefits outweigh the dental risks. MDL 3092 asks a different question: whether the film's makers adequately warned about alleged dental erosion and decay.

Federal proceeding

MDL 3092

Northern District of Ohio before Judge J. Philip Calabrese.

Actions pending

1,827

JPML count as of August 3, 2026, with 1,908 actions listed historically.

FDA warning

January 12, 2022

FDA required dental-risk warnings for buprenorphine medicines dissolved in the mouth.

Core allegation

Dental erosion and decay

Plaintiffs allege inadequate warnings involving brand-name Suboxone film; defendants contest the claims.

Treatment caution

Do not stop abruptly

FDA stresses that buprenorphine's benefits outweigh the dental risk and that treatment changes require clinical guidance.

Documented chronology

How the litigation reached this point

What FDA concluded about the dental signal

Suboxone film contains buprenorphine and naloxone and is placed under the tongue or inside the cheek. Buprenorphine is a partial opioid agonist used to treat opioid use disorder. FDA emphasizes that it reduces withdrawal and craving and can help sustain recovery and reduce overdose risk. The agency's 2022 dental warning said plainly that the benefits of buprenorphine clearly outweigh the reported dental risks.

In the same communication, FDA identified a real safety signal with buprenorphine medicines that dissolve in the mouth. The agency reviewed 305 reported dental cases, 131 of them serious, including cavities, oral infections, and tooth loss. Twenty-six reports involved people with no previous dental problems, and 71 mentioned extraction. The median reported time to diagnosis was about two years, with some problems reported much earlier. FDA cautioned that spontaneous reports establish event types rather than frequency.

Both findings hold at once, which is why 'stop the medicine' is the wrong reading. Abrupt discontinuation can destabilize opioid-use-disorder treatment and raise relapse and overdose risk. The response FDA describes is preventive dental care, correct after-dose oral care, and treatment decisions coordinated between prescriber and dentist.

What FDA now tells patients and clinicians

Current Suboxone labeling has a dedicated dental-adverse-events warning. It describes reported caries, tooth fracture, tooth loss, abscess or infection, erosion, fillings falling out, and restorative treatment. Prescribers are told to ask about oral health, refer patients for dental care soon after starting therapy, and encourage regular checkups. Dentists are advised to perform a baseline assessment and develop a caries-prevention plan.

After the film has completely dissolved, the label advises gently rinsing the teeth and gums with water and swallowing the water, then waiting at least one hour before brushing. The waiting period exists to avoid brushing immediately after oral exposure, when the tooth surface may be vulnerable. These instructions supplement ordinary dental care and change the odds rather than the outcome.

The label also separates reported postmarketing events from clinical-trial rates. Voluntary reports come from a population of uncertain size, so they cannot estimate frequency or establish a causal relationship. That limitation belongs beside the warning rather than beneath it.

What the research adds

A 2022 cohort analysis compared new users of sublingual buprenorphine/naloxone with transdermal buprenorphine and injectable naltrexone using insurance claims, and reported more dental adverse events in the sublingual group. Like other database studies, it worked from coded diagnoses and left several variables unrandomized: formulation choice, baseline dental health, and access to dentistry among them.

A newer retrospective cohort published in 2026 included 14,495 adults with opioid use disorder. Dental events occurred in 2.17% of oral-buprenorphine users and 1.66% of controls, an adjusted hazard ratio of 1.36. That is an association within the studied population. It also groups oral buprenorphine exposure more broadly than a product-liability court, which will look at brand-name film specifically.

Clinical context belongs in the same frame. Randomized and observational treatment studies show buprenorphine retaining patients in treatment and reducing illicit opioid use. A dental-risk discussion that omits those benefits can itself cause harm. The warning question the court will answer and the treatment question a clinician answers run on the same facts toward different decisions.

What MDL 3092 is doing now

The JPML centralized the litigation in February 2024 after finding shared factual questions about the alleged propensity of Suboxone film to cause dental erosion and decay, product development and labeling, and the adequacy of warnings. The court's public MDL page collects case-management orders. The census process asks for proof of brand-name Suboxone film use and dental injury after use, among other records. Those are litigation-screening requirements, not a public promise that a claim will survive or be paid.

The amended bellwether protocol creates progressively narrower groups: a record-collection pool, a core-discovery pool, and a trial-selection pool. A March 2026 schedule set steps for selecting 50 core-discovery cases during June and July 2026. Bellwether selection lets the parties test recurring proof against full records, with each case still proceeding on its own.

As of August 3, 2026, the JPML counted 1,827 pending actions and 1,908 historical actions. The narrow gap indicates that most historically associated actions remained pending on that date. Merits, product proof, and dental causation all sit outside what a docket count can show.

The record trail that matters

Pharmacy records can show whether the dispensed product was brand-name Suboxone film, a generic film, a tablet, or another formulation. Prescriber notes establish indication, dose, and duration. Dental charts can show the baseline condition, the caries and periodontal pattern, and when problems first appeared. Photographs and radiographs may help a dentist interpret progression.

Other factors enter as clinical variables rather than moral judgments. Tobacco use, dry mouth from other medicines, diabetes, and access to dental care all affect dental health. A rigorous review accounts for them, in either direction, instead of treating a person's history as an answer.

Anyone currently taking buprenorphine should raise concerns with the treating clinician and dentist while staying on therapy. A legal review runs separately and depends on product proof, injury chronology, state law, and procedural deadlines. This dossier reports the docket and the regulatory record.

Reader questions

Frequently asked questions